<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308259">
  <stage>Registered</stage>
  <submitdate>24/07/2009</submitdate>
  <approvaldate>25/08/2009</approvaldate>
  <actrnumber>ACTRN12609000730202</actrnumber>
  <trial_identification>
    <studytitle>Concomitant radiotherapy and weekly cisplatin with or without prior induction chemotherapy with cisplatin, epirubicin and paclitaxel (CEP) in patients with locally advanced nasopharyngeal carcinoma</studytitle>
    <scientifictitle>Induction chemotherapy with  cisplatin,  epirubicin and paclitaxel (CEP), followed by concomitant radiotherapy and weekly  cisplatin versus the same concomitant chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
A randomized phase II study conducted by the Hellenic Cooperative Oncology Group</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Locally advanced nasopharyngeal carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Epirubicin 75 mg/m2 in 20 min infusion followed by paclitaxel 175 mg/m2 in 3-hr infusion, preceded by standard premeditation, on day 1 and cisplatin 75 mg/m2 in 2-hr infusion on day 2. Each cycle will be repeated every 3 weeks. 
Cisplatin prehydration
2 liters of glucose 5% solution intravenous (IV) + 6 g of Sodium Chloride (NaCL)/l IV + 2 g Potassium Chloride(KCL)/l IV to be infused in 3 hours. 
Mannitol 10% solution 250 ml in 1/2 hour before cisplatin; cisplatin 100 mg/m2 in 125 ml normal saline + 250 ml of mannitol in 1 hour. 
Cisplatin posthydration 
2 liters of glucose 5% solution + 6 g NaCl/l and 2 g KCl/l. 
1 vial/l of magnesium sulphate, in 3 hours.
Cisplatin 40 mg/m2 in 1 hour infusion weekly x 7, 1 h prior to radiotherapy (RT) will be administered during the RT period.</interventions>
    <comparator>Cisplatin 40 mg/m2 in 1 hour infusion weekly x 7, 1 h prior to RT will be administered during the RT period.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate (ORR). The ORR will be assessed by imaging methods including computed tomography (CT) scan and magnetic resonance imaging (MRI) of the head and neck region</outcome>
      <timepoint>2-3 months after the completion of chemoradiotherapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>Patients will be followed-up for 3 years after entering the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS)</outcome>
      <timepoint>Patients will be followed-up for 3 years after entering the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>acute toxicity</outcome>
      <timepoint>6 months after study completion. Toxicity is assessed by laboratory evaluation of hematology and biochemistry, physical examination etc.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>We will also conduct translational research studies to assess tumor samples for predictive biomarkers.</outcome>
      <timepoint>Research studies will commence following collection of tumour samples for up to 5 years following completion of this study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Disease characteristics:
1.Biopsy - proven, previously untreated, World Health Organisation (WHO)  type I, II or undifferentiated NPC. 
2.Stage IIB-IVB [Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)]  after pre-therapeutic extensive workup 3.Measurable or evaluable disease required. 
3. No synchronous primary tumors.
4. Chest x-ray, bone scan and liver imaging prior to initiation of treatment.
5. Computed tomography (CT) scan and/or Magnetic Resonance Imaging (MRI) of the head and neck region prior to initiation of treatment. 
Patient characteristics: 
1. Age: 15 years and over.
2. Performance status: WHO 0 - 2
3. Hematopoietic: White Blood Cells (WBC) &gt; 3,500 and platelets &gt;100,000.
4. Renal: creatinine clearance &gt;50 ml/min (measured or calculated) and serum calcium normal.
5. Hepatic: Alkaline phosphatase (ALP) and Serum glutamic oxaloacetic transaminase (SGOT) normal.
6.Cardiovascular: status adequate to tolerate all protocol treatment. 
7.Pulmonary: status adequate to tolerate all protocol treatment.
8.Nutritional status: status adequate to tolerate all protocol treatment.
9.Mental status: adequate to follow instructions, keep appointments and provide written informed consent prior to study entry.
10.Life expectancy of at least 3 months.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior therapy:
No prior biologic, chemotherapy, surgery or radiotherapy to the head and neck is allowed.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>3/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>148</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Hellenic Cooperative Oncology Group</primarysponsorname>
    <primarysponsoraddress>18, Hatzikostandi str, 11524, Athens</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Hellenic Cooperative Oncology Group</fundingname>
      <fundingaddress>18, Hatzikostandi str, 11524, Athens</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this phase II randomized study was to compare the overall response rate (ORR), the progression-free survival (PFS), the overall survival (OS) and the acute toxicity of previously untreated patients with locally advanced non-nasopharyngeal carcinoma (LA-NPC).Patients were randomized to either 3 cycles of IC with cisplatin 75mg/m2, epirubicin 75mg/m2 and paclitaxel 175mg/m2 (CEP) every 3 weeks followed by definitive radiotherapy 70 Gy and concomitant weekly cisplatin 40mg/m2 (CCRT) or CCRT alone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>George Fountzilas</name>
      <address>"Papageorgiou" Hospital, Nea Efkarpia, Thessaloniki, 564 29</address>
      <phone>+302310693959</phone>
      <fax>+302310683136</fax>
      <email>fountzil@auth.gr</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eleni Papakostaki</name>
      <address>Hellenic Cooperative Oncology Group
18, Hatzikostandi str, 11524 Athens</address>
      <phone>+302106912520</phone>
      <fax>+302106912713</fax>
      <email>hecogoff@otenet.gr</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address>Hellenic Cooperative Oncology Group
18, Hatzikostandi str, 11524 Athens</address>
      <phone>+302106912520</phone>
      <fax>+302106912713</fax>
      <email>hecogoff@otenet.gr</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>